Non-Hodgkins Lymphoma, Prostate Cancer
Conditions
Keywords
SGI-1776, PIM, Hormone & Docetaxel refractory Prostate Cancer, Refractory non-Hodgkin's Lymphoma
Brief summary
Patients with hormone and docetaxel refractory prostate cancer or relapsed/refractory non-Hodgkin's lymphoma for which no available standard therapy or therapy which may provide clinical benefit is available will be enrolled. Primary objectives: estimate the maximum tolerated dose and dose-limiting toxicities. Secondary objectives: Response rate, pharmacokinetic and pharmacodynamic profiles, Prostate Specific Antigen response and renal elimination.
Interventions
DRUGSGI-1776
Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
Sponsors
Astex Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: 1. Read, understand and sign the IRB- or IEC-approved ICF confirming his or her willingness to participate in this trial. 2. At least 18 years old. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 4. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function. 5. Normal cardiac function in the opinion of the investigator and supported by LVEF 50% or greater on the screening echocardiogram (or MUGA), no significant abnormalities on the screening ECG (eg, left bundle branch block, III degree AV block, acute myocardial infarction, Wolff-Parkinson-White syndrome or QTc interval ≥ 450 msec) and no history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia or family history of Long QT Syndrome).
Exclusion criteria
1. Active secondary malignancy or history of other malignancy within the last two years except non-melanoma skin cancers or cervical carcinoma in situ. 2. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. 3. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or marketed or investigational tyrosine kinase inhibitors. 4. Received prior radiation therapy within the past 4 weeks or received irradiation of ≥ 25% of their bone marrow reserve. 5. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV. 6. Symptomatic CNS metastases or lesions for which treatment is required. Prostate Cancer Inclusion Criteria: 1. Males with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g., any T, any N, M1a-c)based on bone scan, CT scan, or MRI scan. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy. 2. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy. • Greater than 25% increase in 3 consecutive tests (PSA 1 \< PSA 2 \< PSA 3), each PSA value separated by at least 1 week 3. Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist. 4. At least 4 weeks since prior flutamide, megestrol, ketoconazole, aminoglutethimide; and at least 6 weeks since prior bicalutamide or nilutamide. 5. Systemic corticosteroids discontinued within two weeks of dosing, except low dose regimens which may continue if unchanged 6. Strontium-89 or Samarium-153 must have been completed at least 8 weeks prior to the first dose of therapy and recovered from all treatment-related toxicities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD & DLT | July 2011 |
Secondary
| Measure | Time frame |
|---|---|
| Response rate, pharmacokinetics, PSA response, renal elimination and pharmacodynamic effects on biomarker modulation. | July 2011 |
Countries
United Kingdom, United States
Outcome results
None listed